# Combination Chemotherapy Plus Amifostine in Treating Patients With Advanced Cancer

> **NCT00004036** · PHASE1 · UNKNOWN · sponsor: **The Cleveland Clinic** · enrollment: 30 (estimated)

## Conditions studied

- Chronic Myeloproliferative Disorders
- Drug/Agent Toxicity by Tissue/Organ
- Leukemia
- Lymphoma
- Multiple Myeloma and Plasma Cell Neoplasm
- Myelodysplastic Syndromes
- Precancerous Condition
- Unspecified Adult Solid Tumor, Protocol Specific

## Interventions

- **BIOLOGICAL:** sargramostim
- **DRUG:** amifostine trihydrate
- **DRUG:** carboplatin
- **DRUG:** cyclophosphamide

## Key facts

- **NCT ID:** NCT00004036
- **Lead sponsor:** The Cleveland Clinic
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 1997-11
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2013-12-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00004036

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00004036, "Combination Chemotherapy Plus Amifostine in Treating Patients With Advanced Cancer". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT00004036. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*